Collaboration will leverage Belharra’s proprietary, non-covalent chemoproteomics platform to identify and advance small molecules against Sanofi-designated immunology targets Sanofi to lead further preclinical, clinical and commercial activities of candidates Belharra is eligible to receive up to $40 million in upfront and near-term milestone payments, and up to nearly$700 million in aggregate research, development and commercial milestone payments and royalties on net sales SAN MATEO, Calif. AND SAN DIEGO ...